GEN News Highlights

Newly established Puma Biotechnology acquired global development and commercialization rights to Pfizer’s Phase III-stage anticancer drug neratinib. The orally administered drug is a multitargeted, irreversible tyrosine kinase inhibitor that targets the ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4) kinases. It is an irreversible tyrosane kinase inhibitor, which is in development for the treatment of early- and late-stage HER2-positive breast cancer.

Pfizer acquired neratinib when it took over Wyeth back in 2009, but says while oncology remains a priority, it is actively prioritizing its portfolio to decide which compounds to develop internally and which to outlicense. Under terms of the deal with Puma, Pfizer will receive milestones related to development of neratinib, plus sales royalties.

Puma is focused on licensing in anticancer drugs for development. The firm has been set up by Alan H. Auerbach, who also founded and was CEO at Cougar Biotechnology, which Johnson & Johnson took over in 2009.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.